Risedronate in Osteopenic Postmenopausal Women

Summary

Risedronate in Osteopenic Postmenopausal Women is a clinical trial^[1].

Key Facts

• Risedronate in Osteopenic Postmenopausal Women is in the country of France^[2].
• Risedronate in Osteopenic Postmenopausal Women's instance of is recorded as clinical trial^[3].
• Risedronate in Osteopenic Postmenopausal Women's start time is recorded as +2006-03-31T00:00:00Z^[4].
• Risedronate in Osteopenic Postmenopausal Women's end time is recorded as +2009-06-30T00:00:00Z^[5].
• Risedronate in Osteopenic Postmenopausal Women's main subject is recorded as osteoporosis^[6].
• Risedronate in Osteopenic Postmenopausal Women's number of participants is recorded as {'unit': '1', 'amount': '+156'}^[7].
• Risedronate in Osteopenic Postmenopausal Women's title is recorded as A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo^[8].
• Risedronate in Osteopenic Postmenopausal Women's short name is recorded as OSMAUSE^[9].
• Risedronate in Osteopenic Postmenopausal Women's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}^[10].
• Risedronate in Osteopenic Postmenopausal Women's ClinicalTrials.gov ID is recorded as NCT00345644^[11].
• Risedronate in Osteopenic Postmenopausal Women's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}^[12].
• Risedronate in Osteopenic Postmenopausal Women's research intervention is recorded as risedronic acid^[13].
• Risedronate in Osteopenic Postmenopausal Women's clinical trial phase is recorded as phase III clinical trial^[14].
• Risedronate in Osteopenic Postmenopausal Women's research site is recorded as Sanofi^[15].
• Risedronate in Osteopenic Postmenopausal Women's study type is recorded as interventional study^[16].